News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Applied NeuroSolutions, Inc. (APNS.OB) Updates Promising Results for a Blood-Based Test for Alzheimer's Disease

10/9/2009 6:40:14 AM

Bookmark and Share

VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc., a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today confirmed, as previously disclosed in July 2009, that it has achieved sufficient analytical sensitivity to detect tau in serum patient samples. This is a key step in the development of a blood-based test to detect AD at an early stage. Based on a further analysis of the preliminary data, the Company believes additional development of the assay, including optimization and validation in key patient population groups, is necessary to determine the specific sensitivity and specificity performance of the assay. The Company is currently raising funds to support continued development and commercialization of this blood-based Alzheimer’s test.

Applied NeuroSolutions, Inc. also announces the Company website has been updated, including a current Corporate Presentation.

About Applied NeuroSolutions:

Applied NeuroSolutions, Inc. (OTC BB:APSN - News) is developing diagnostics and therapeutics to detect and treat Alzheimer's disease (AD) building on discoveries originating from the Albert Einstein College of Medicine. Applied NeuroSolutions is in a collaboration with Eli Lilly and Company to develop novel therapeutic compounds to treat the progression of AD. For its diagnostic pipeline, Applied NeuroSolutions is focused on both cerebrospinal fluid (CSF) and serum tests to detect AD at a very early stage. The CSF based P-Tau 231 test now being offered for use in clinical trials can effectively differentiate AD patients from those with other neurological diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect AD. Alzheimer's disease currently afflicts over five million Americans, and the world market for AD therapy is currently estimated to be nearly 30 million patients. For more information, visit

This press release contains forward-looking statements about Applied NeuroSolutions. The company wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at, and review the company's filings with the Securities and Exchange Commission.


Applied NeuroSolutions, Inc. 847-573-8000 Craig Taylor, President and CEO David Ellison, CFO

Read at

comments powered by Disqus